Daniel Mueller is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
516 Delaware Street SE, Clinic 6a
University Of Minnesota Physicians
Minneapolis, MN 55455
Telephone
612-625-8690Registry record last updated 26 Oct 2012.
Clinical trials
- Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)
Sponsor: Croma-Pharma GmbH
- Detection of Pathological Lymphocytes in Patients With Autoimmune Disease
Sponsor: University of Minnesota
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.4%Folate Analog Metabolic Inhibitor19.3%Methotrexate100%Part D≥38 patientsTNF inhibitor8.6%Humira Pen30%Humira(Cf) Pen26%Cimzia (2 Pack)23%Enbrel Sureclick21%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
28%Corticosteroid13.4%Prednisone100%Part D≥32 patientsAminosalicylate9.1%Sulfasalazine54%Sulfasalazine Dr46%Part D<11 patients+ 2 more classes in this area
Nervous system
17%Cholinergic Receptor Agonist6.8%Cevimeline Hcl52%Pilocarpine Hcl48%Part D<11 patientsGabapentinoids6.6%Gabapentin100%Part D≥14 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 1992–2025 per NIH RePORTER. The latest:
- Medical Student Summer Research Program in Infection and Immunity
University of Minnesota
FY2025$42,258T35AI118620 - Medical Student Summer Research Program in Infection and Immunity
University of Minnesota
FY2024$34,558T35AI118620 - Functional characterization of anergic helper T cells
University of Minnesota
FY2023$359,110P01AI035296
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”